Department of Biochemistry, National Institute for Research in Reproductive Health (ICMR-NIRRH), Parel, Mumbai, India.
ICMR Biomedical Informatics Centre, National Institute for Research in Reproductive Health (ICMR-NIRRH), Parel, Mumbai, India.
Virus Res. 2019 Nov;273:197763. doi: 10.1016/j.virusres.2019.197763. Epub 2019 Sep 22.
Human Immunodeficiency Virus-1 Clade C (HIV-1C) dominates the AIDS epidemic in India, afflicting 2.1 million individuals within the country and more than 15 million people worldwide. Membrane proximal external region (MPER) is an attractive target for broadly neutralizing antibody (bNAb) based therapies. However, information on MPER sequence diversity from India is meagre due to limited sampling of primary viral sequences. In the present study, we examined the variation in MPER of HIV-1C from 24 individuals in Mumbai, India by high throughput sequencing of uncultured viral sequences. Deep sequencing of MPER (662-683; HXB2 envelope amino acid numbering) allowed quantification of intra-individual variation up to 65% at positions 662, 665, 668, 674 and 677 within this region. These variable positions included contact sites targeted by bNAbs 2F5, Z13e1, 4E10 as well as 10E8. Both major and minor epitope variants i.e. 'haplotypes' were generated for each sample dataset. A total of 23, 34 and 25 unique epitope haplotypes could be identified for bNAbs 2F5, Z13e1 and 4E10/10E8 respectively. Further analysis of 4E10 and 10E8 epitopes from our dataset and meta-analysis of previously reported HIV-1 sequences from India revealed 26 epitopes (7 India-specific), heretofore untested for neutralization sensitivity. Peptide-Ab docking predicted 13 of these to be non-binding to 10E8. ELISA, Surface Plasmon Resonance and peptide inhibition of HIV-1 neutralization assays were then performed which validated predicted weak/non-binding interactions for peptides corresponding to six of these epitopes. These results highlight the under-representation of 10E8 non-binding HIV-1C MPER sequences from India. Our study thus underscores the need for increased surveillance of primary circulating envelope sequences for development of efficacious bNAb-based interventions in India.
人类免疫缺陷病毒 1 型 C 群(HIV-1C)在印度艾滋病流行中占主导地位,该国受影响的人数达 210 万,全球超过 1500 万人。膜近端外区(MPER)是广泛中和抗体(bNAb)治疗的一个有吸引力的靶点。然而,由于对原发性病毒序列的有限采样,来自印度的 MPER 序列多样性信息非常有限。在本研究中,我们通过高通量测序未培养的病毒序列,检测了来自印度孟买 24 个人的 HIV-1C 的 MPER 变异。MPER(HXB2 包膜氨基酸编号 662-683)的深度测序可定量该区域内 662、665、668、674 和 677 位的个体内变异高达 65%。这些可变位置包括 bNAb 2F5、Z13e1、4E10 和 10E8 靶向的接触位点。每个样本数据集都生成了主要和次要表位变体,即“单倍型”。可以分别为 bNAb 2F5、Z13e1 和 4E10/10E8 鉴定出总共 23、34 和 25 个独特的表位单倍型。对来自我们数据集的 4E10 和 10E8 表位的进一步分析和对以前报道的来自印度的 HIV-1 序列的荟萃分析显示,有 26 个表位(7 个印度特有)以前未测试过中和敏感性。肽-抗体对接预测其中 13 个与 10E8 不结合。然后进行 ELISA、表面等离子体共振和肽抑制 HIV-1 中和测定,验证了对应于其中 6 个表位的肽的预测弱/不结合相互作用。这些结果突出表明,印度 HIV-1C MPER 序列中 10E8 非结合序列代表性不足。因此,我们的研究强调需要增加对主要循环包膜序列的监测,以在印度开发有效的 bNAb 为基础的干预措施。